A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions

Renal ImpairmentEnd-stage Kidney DiseaseHealthy Participants

Interventions

DRUG

AZD4144

AZD4144 will be administered orally.

Trial Locations (2)

Research Site, Sofia

Research Site, Bucharest